Circular RNA circMYBPC1 promotes skeletal muscle differentiation by targeting MyHC

Mengjie Chen,1,4 Xuefeng Wei,2,4 Mingming Song,1 Rui Jiang,1 Kongwei Huang,1 Yanfei Deng,1 Qingyou Liu,1 Deshun Shi,1 and Hui Li1

1State Key Laboratory for Conservation and Utilization of Subtropical Agro-Bioresources, College of Animal Science and Technology, Guangxi University, Nanning 530004, China; 2College of Life Sciences, Xinyang Normal University, Institute for Conservation and Utilization of Agro-Bioresources in Dabie Mountains, Xinyang, Henan 464000, China; 3Institute for Stem Cell and Regeneration, Chinese Academy of Sciences, Beijing 100101, China

Skeletal muscle development is a complex and highly orchestrated biological process mediated by a series of myogenesis regulatory factors. Numerous studies have demonstrated that circular RNAs (circRNAs) are involved in muscle differentiation, but the exact molecular mechanisms involved remain unclear. Here, we analyzed the expression of circRNAs at the adult and embryo development stages of cattle *musculus longissimus*. A stringent set of 1,318 circRNAs candidates were identified, and we found that 495 circRNAs were differentially expressed between embryonic and adult tissue libraries. We subsequently focused on one of the most downregulated circRNAs (using the adult stage expression as control), and this was named muscle differentiation-associated circular RNA (circMYBPC1). With RNA binding protein immunoprecipitation (RIP) and RNA pull-down assays, circMYBPC1 was identified to promote myoblast differentiation by directly binding miR-23a to relieve its inhibition on myosin heavy chain (*MyHC*). In addition, RIP assays demonstrated that circMYBPC1 could directly bind MyHC protein. *In vivo* observations also suggested that circMYBPC1 may stimulate skeletal muscle regeneration after muscle damage. These results revealed that the novel non-coding circRNA circMYBPC1 promotes differentiation of myoblasts and may promote skeletal muscle regeneration. Our results provided a basis for in-depth analysis of the role of circRNA in myogenesis and muscle diseases.

INTRODUCTION

During animal farming, the quality and quantity of meat are directly affected by the development of skeletal muscle.1 In medicine, numerous muscle diseases are related to abnormal development of skeletal muscles. Skeletal muscle development is a highly orchestrated biological process involving cell proliferation, differentiation, fusion, migration, and apoptosis.2 After the mesenchymal stem cells derived from the embryonic mesoderm differentiate into mononuclear myoblasts, these cells migrate and fuse to form multinucleated myotubes, which further differentiate into muscle fibers, and finally the muscle fibers grow and mature into skeletal muscle.3,4 This progression of skeletal muscle development involves complex gene regulatory networks and several signal transduction pathways. The normal development of skeletal muscles benefits from the programmed expression of a series of important genes, such as myogenic regulatory factors (MRFs)5-6 and myocyte enhancer factor 2 (MEF2).7,8 However, the existing research into these processes of muscle development is still in its infancy, and the functions of several new regulatory factors and molecular mechanisms urgently need to be further explored. This will, in turn, improve meat production in farm animals and help to develop potential new treatments for muscle disorders and diseases.

In recent decades, numerous non-coding RNAs have been found to be related to skeletal muscle development, such as microRNAs (miRNAs),9 long non-coding RNAs (lncRNAs),10 and circular RNAs (circRNAs).11 As early as 1991, circRNAs were found in human cells12 possessing covalently closed-loop structures,13 but their existence was only verified in 2013.14,15 circRNAs localized to different subcellular components function by regulating gene transcription and post-transcriptional translation.16,17 Sry and ciRS-7 are well known as competing endogenous RNAs (ceRNAs) to bind miR-138 and miR-7, respectively, suggesting their roles in post-transcriptional regulation.15,18 circLMO7, circFUT10, and circFGFR4 have been reported as ceRNAs to bind miRNAs and affect muscle development.19-21 In addition, circRNAs act as molecular scaffolds to regulate the transcription and epigenetic modification of chromatin. For example, EIciRNA is able to induce host-gene transcription by interacting with RNA Pol II in cis.22

The purpose of this research is to characterize circRNAs that have potential functions in cattle muscle development. Angus cattle has a reputation for providing meat of excellent qualities, it is known as one of the best beef cattle, and it is one of the most raised beef cattle breeds in China. Here, we took the first steps to characterize circRNA...
expression profiles in Angus cattle *musculus longissimus* from the fetus and adult developmental stages, applying the Ribo-Zero RNA sequencing (RNA-seq) method. Then, we focused on the functions of one of the most downregulated circRNAs, circRNA0007120, which was subsequently named as circMYBPC1 according to its host gene MYBPC1. Mechanistically, circMYBPC1 positively upregulated the expression of myosin heavy chain (MyHC) by directly interacting with miR-23a and binding MyHC protein, respectively, in order to induce myoblast differentiation *in vitro* and promote muscle regeneration *in vivo*. These results will not only provide a valuable transcriptional regulatory resource for understanding the mechanisms of cattle muscle development but may also reveal new clues for identifying the role of circRNAs in myogenic differentiation and muscle diseases.

RESULTS

**Expression profiles of circRNAs in Angus cattle skeletal muscle**

Numerous RNAs were identified from six longissimus muscle samples of Angus cattle at the fetus (90 days old) and adult (24 months old) stages by removing the ribosomal RNA-seq (Table 1). After removal of ribosomal RNA (rRNA), 1,318 circRNA candidates were identified (Table 2). Our results showed that the genomic loci of circRNA were widely distributed throughout the chromosome (Figure 1A). Longer chromosomes produce more reads, which indicates that the number of circRNAs produced in chromosomes may increase with the length of chromosomes. To identify the circRNAs that have potential functions in the development of cattle muscle, we counted the circRNAs found. The results indicated that there were 39 circRNAs specifically in the fetal library and 527 circRNAs in the adult library (Figure 1B). The statistical results showed that ~77.98% of circRNAs were derived from exons and ~16.37% were derived from intergenic regions, but only a few (5.66%) circRNAs were derived from the introns (Figures 1C and 1D).

**Differentially expressed circular RNAs**

From the adjusted level of significance and the fold change, a total of 495 differentially expressed circRNAs were identified. The differential circRNAs were screened, and it was found that 383 circRNAs were downregulated and 112 circRNAs were upregulated when comparing adult with fetus muscle tissues (Figure 2A; Table S1). In order to determine whether the expression levels of circRNAs were consistent with those of host genes, the upregulated and downregulated expression of circRNAs (n = 495) were compared directly with the corresponding mRNA (n = 86) expression that changed between the fetus- and adult-stage libraries. At different developmental stages, the expression patterns of many circRNAs were not consistent with the changes of host genes, and it was hard to explain the variation of circRNA expression by the change of mRNA expression. This strongly suggests that the random by-products from mRNA precursor classical splicing are not the main source of circRNAs (Figure 2B).

In addition, Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses were employed to predict the function of circRNAs and the signal transduction pathways (Figures 2C and 2D; Tables S2 and S3). The results indicated that there were several circRNAs that were involved in the processes related to muscle development, such as muscle structure development and muscle cell differentiation. To further clarify the potential function of circRNAs, a cluster heatmap of candidate circRNAs was constructed (Figure 2E), which displayed the abundance of the maternal gene transcripts of the top 100 circRNAs with the largest differences (Figures 2F and 2G). Moreover, the expression patterns of differentially expressed circRNAs were consistent with their host genes. However, the expression levels of differentially expressed circRNAs (mean transcripts per million [TPM] = 1,063.91) were markedly higher than host genes (mean fragments per kilobase of exon model per million reads mapped [FPKM] = 46.0), suggesting that circRNAs are produced by purposeful transcription as opposed to transcriptional junk events (Tables S1 and S4).

**Characteristics of circRNAs in cattle skeletal muscle**

Analysis of the characteristics of circRNA in bovine muscle tissue revealed that most circRNA contains 1 to 4 exons (Figure 3A), and ~1 to 8 circRNAs may be produced from a parental gene (Figure 3B). The length of most circRNAs is <2,000 nucleotides (nt), with an average length of 800 nt (Figure 3C; Table 2). In addition, the expression levels of most circRNAs in cattle muscle during the fetal and adult stages tend to have TPM of <1,000 (Figure 3D).

**Competing endogenous RNA network**

In order to construct a ceRNA network, we performed bioinformatics analysis on all differentially expressed circRNAs and predicted their binding miRNAs. Most of these selected miRNAs seem to be related to muscle development (Figure 4A). Moreover, we selected differentially expressed circRNAs and randomly selected 5 differentially
expressed circRNAs with more than three binding sites; we also selected 21 miRNAs and 88 mRNAs, which were differentially expressed, to construct an interaction network: the circRNA-miRNA-mRNA interaction network (Figure 4B). For example, circRNA0007120, which was one of the most downregulated of the circRNAs, had multiple miRNA binding sites, and these miRNAs have already been proven to regulate muscle development.

Identification of circMYBPC1 as a candidate circRNA
Previous studies have shown that circRNA can competitively bind miRNA with target genes, thereby eliminating the negative effect of miRNA on target gene expression. In our sequencing data, we discovered that circRNA0007120 was specifically expressed in skeletal muscle; tissue expression assays confirmed the accuracy of our sequencing data (p < 0.05; Figure 5A), and this indicated that circRNA0007120 affects the process of muscle development. Therefore, circRNA0007120 was chosen as a candidate circRNA that affects muscle development, and it was termed circMYBPC1, which was transcribed from MYBPC1 gene in chromosome 27 with a full length of 398 nt (Text S1). Our sequencing data showed that circMYBPC1 was differentially expressed in cattle fetal and adult muscle tissues (Table S1). Subsequently, we performed quantitative detection of circMYBPC1, which was consistent with the sequencing results (p < 0.05; Figure 5B). To determine the role of circMYBPC1 in cattle myogenesis, we examined the expression pattern of circMYBPC1 in different tissues (heart, liver, spleen, lung, kidney, small intestine, muscle; tissue expression assays confirmed the accuracy of our sequencing data (p < 0.05; Figure 5A)), and this indicated that circRNA0007120 affects the process of muscle development. Therefore, circRNA0007120 was chosen as a candidate circRNA that affects muscle development, and it was termed circMYBPC1, which was transcribed from MYBPC1 gene in chromosome 27 with a full length of 398 nt (Text S1). Our sequencing data showed that circMYBPC1 was differentially expressed in cattle fetal and adult muscle tissues (Table S1). Subsequently, we performed quantitative detection of circMYBPC1, which was consistent with the sequencing results (p < 0.05; Figure 5B). To determine the role of circMYBPC1 in cattle myogenesis, we examined the expression pattern of circMYBPC1 in different tissues (heart, liver, spleen, lung, kidney, small intestine, musculus longissimus, leg muscle, stomach) of Angus cattle by quantitative real-time PCR (n = 3), circMYBPC1 had higher expression in muscle tissue than other tissues (Figure 5C). Furthermore, the expression of circMYBPC1 in myoblasts at the cell differentiation stage was higher than that in the proliferation phase, suggesting potential roles of circMYBPC1 in muscle cell differentiation (p < 0.05; Figures 5D and 5E). RNase R digestion assays further demonstrated that circRNA0007120 had a circular structure (Figure 5F). The results of nucleoplasmic separation and fluorescence in situ hybridization (FISH) assays indicated that circMYBPC1 was preferentially distributed in the cytoplasm (Figures 5G and 5H). Subsequently, a circMYBPC1 expression plasmid, pCD2.1-circMYBPC1 (Figure S1B), was transfected into muscle cells that could significantly enhance circMYBPC1 expression level (p < 0.05; Figure 5I). MyoD, myogenin (MyoG), and MyHC were measured in cattle muscle cells treated with pCD2.1-circMYBPC1 (Figure S1B) and then differentiated for 4 days. Overexpression of circMYBPC1 was seen to markedly increase the expression of MyoD, MyoG, and MyHC (p < 0.05; Figures 6A and 6B). In addition, miR-23a suppressed the protein expression of MyoD, MyoG, and MyHC, and these effects were eliminated by overexpression of circMYBPC1 (Figures 6A and 6B). From the results of immunofluorescence assays, circMYBPC1 was also found to promote MyHC expression and myotube formation in muscle cells (p < 0.05; Figures 6C and 6D).

Effects of circMYBPC1 on cell proliferation
To explore the function of circMYBPC1 during muscle cell proliferation, pCD2.1-circMYBPC1 was transfected into bovine primary myoblasts. Flow cytometry analysis revealed that the number of muscle cells in the G1 and S phases did not change significantly (p > 0.05; Figures 7A and 7B). The key proteins of cell proliferation such as CDK2 and PCNA were measured by western blotting and quantitative real-time PCR. The results indicated that overexpression of circMYBPC1 could not affect their expression levels significantly (p > 0.05; Figures 7C and 7D). Cell Counting Kit-8 (CCK-8) assays were also performed to measure the effect of circMYBPC1 on cell proliferation, and it was found that cell viability could be slightly inhibited by circMYBPC1, but this did not reach significance (p > 0.05; Figure 7E). Similar results were also obtained by 5-ethyl-2'-deoxyuridine (EdU) assays (p > 0.05; Figures 7F and 8G). These data demonstrated that circMYBPC1 had no effect on bovine myoblast proliferation.

circMYBPC1 acts as a ceRNA for miR-23a
As mentioned above, circMYBPC1 is located mainly in the cytoplasm of bovine skeletal muscle cells. We speculated that circMYBPC1 might function as a ceRNA to cause inhibition of miRNAs for its target genes. The online prediction software RNAhybrid revealed that circMYBPC1 had four putative miR-23a binding sites (Text S2). In order to verify whether miR-23a targets circMYBPC1, miR-23a mimics were co-transfected with psi-CHECK2 dual-luciferase reporters containing the full sequence of circMYBPC1 into 293T cells for luciferase activity analysis, and we found that only overexpression of miR-23a reduced the luciferase activity (p < 0.05; Figure 8B). To further validate the targeting relationship between miR-23a and circMYBPC1, sensor elements, comprising the complementary strand (2×) of miR-23a mature sequence, were constructed (p < 0.05; Figure 8C). The sensor elements were co-transfected with their respective miR-23a mimics, and the RLuc luciferase activity was found to decrease significantly, indicating that the sensor elements allow binding to the miRNA. Moreover, after addition of the expression vector of circMYBPC1, the luciferase activity was significantly increased (p < 0.05; Figure 8D). To explore that circMYBPC1 could bind miR-23a directly, RIP and RNA pull-down assays were

| Item | circRNA | Min. length (nt) | Mean length (nt) | Median length (nt) | N90 | Max. length (nt) | Total length (nt) |
|------|---------|-----------------|-----------------|-------------------|-----|----------------|------------------|
| Number | 1,318 | 210 | 10,743 | 6,821 | 5,716 | 93,996 | 14,160,180 |
performed using Ago2 antibody (p < 0.05; Figure 8E) and biotinylated miR-23a mimics (p < 0.05; Figure 8F), respectively, and semiquantitative PCR was applied to confirm the interaction between circMYBPC1 and miR-23a. These results revealed that circMYBPC1 could indeed bind miR-23a directly. Previous studies have revealed that miR-23a targets MyHC to regulate myoblast differentiation, which is a major myogenic regulatory factor for myogenesis.26,27 Our studies also confirmed that overexpression of miR-23a causes a decrease in MyHC mRNA and protein levels, whereas overexpression of circMYBPC1 can rescue MyHC expression (p < 0.05; Figure 8G). Together, these results suggest that circMYBPC1 can act as a decoy by directly binding miR-23a in order to relieve the miRNA inhibiting effect on MyHC.

**circMYBPC1 binding to MyHC protein**

Considering that circMYBPC1 is located mainly in the cytoplasm and can promote bovine muscle cell differentiation by regulating MyHC expression, the possibility that circMYBPC1 can bind to MyHC protein directly, in order to play a regulatory role, was explored. The online software RPISeq (http://pridb.gdcb.iastate.edu/RPISeq/#opennewwindow) was therefore used to analyze the possibility of circMYBPC1 binding with MyHC protein. The results showed that circMYBPC1 had a strong binding probability with MyHC protein (Figure 9A). The results of RIP assays also indicated that MyHC protein antibodies could capture circMYBPC1 (p < 0.05; Figures 9B and 9C), and this confirmed the predicted results of RPISeq and demonstrated that circMYBPC1 might exert its biological function through MyHC. Finally, circRNA expressions in bovine muscles of different breeds and different development stages were analyzed. It was found that the circMYBPC1 expression levels in adult muscles were higher than those found in the calf tissues (p < 0.05; Figure 9D). Therefore, circMYBPC1 may become an effective candidate target for altering cattle muscle mass.
circMYBPC1 promotes skeletal muscle regeneration

To explore the effect of circMYBPC1 in skeletal muscle development in vivo, cardiotoxin (CTX) was injected into C57BL/6 mice to induce muscle injury of tibialis anterior muscle. The circMYBPC1 overexpression plasmid was subsequently transfected in vivo, and the experimental results showed that the expression of circMYBPC1 transfected in vivo was significantly increased after skeletal muscle injury (p < 0.05; Figures 10A and 10C). After muscle injury, it was found that the mRNA expression levels of MyoD, PCNA, CyclinD1, and PAX 7 increased significantly (p < 0.05, Figures 10B and 10D), indicating that circMYBPC1 has a certain positive effect on repairing muscle injury. Hematoxylin and eosin (H&E) staining analysis showed that the muscle fibers in the circMYBPC1 group were basically repaired, and the number of healthy fibers was significantly increased compared with the control group (Figures 10E and 10F). According to the immunofluorescence results, the expression levels of PAX 7 and MyoD were considerably increased in transfected cells (p < 0.05; Figure 11). These results indicate that circMYBPC1 may stimulate skeletal muscle regeneration in vivo.

DISCUSSION

In this study, circRNAs related to cattle muscle development were analyzed and annotated by RNA-seq. A novel circRNA, circMYBPC1,
has been identified, which is involved in skeletal muscle development. The results of in vitro experiments indicated that circMYBPC1 promoted myogenesis and myotube formation in cattle skeletal muscle development. Consequently, the overexpression of circMYBPC1 was proven to promote muscle regeneration by in vivo experiments. It was previously reported that circRNAs are involved in the regulation of gene expression during muscle development. The regulatory mechanism of circRNAs is related to their position in the cell. In the nucleus, circRNAs can act as molecular scaffolds to recruit transcription factors or transcriptase to regulate gene transcription. In the cytoplasm, a circRNA could compete with a target gene to bind certain miRNAs in order to reduce the latter’s inhibitory effect on the former. For example, circFUT10 and circFGFR4 alleviate their inhibitory effects on Wnt3a and SRF by combining miR-133a and miR-107, respectively, so as to regulate myogenesis.

In this study, we identified a novel circRNA transcript, subsequently named circMYBPC1, and demonstrated its higher expression in skeletal muscle. Moreover, circMYBPC1 was localized mainly in the cytoplasm, and therefore we focused on its ability to bind miRNAs or RNA binding protein. Using a combination of RNA pull-down, RIP, and luciferase reporter assays, we provided direct evidence that circMYBPC1 could act as a ceRNA and directly bind MyHC protein to increase the expression of MyHC at the mRNA and protein levels and further promote cell differentiation. Myogenesis is initiated in the embryonic mesoderm and is a highly orchestrated biological process. The variable rate of skeletal muscle contraction depends on the polymorphism of MyHC. We investigated whether miR-23a downregulated the expression of the MyHC through binding the 3’ UTR of the mRNAs. In this study, we provide direct evidence that circMYBPC1 could reverse the inhibitory effect of miR-23a on MyHC expression in bovine primary myoblasts. Moreover, circMYBPC1 could directly bind MyHC protein and increase its expression, revealing that circMYBPC1 might exert its biological functions through MyHC.

Skeletal muscle dysplasia is responsible for a large number of muscle diseases, such as muscle hypertrophy, atrophy, and primary muscle disorders. Several lines of research have revealed that non-coding RNAs are crucial for muscle regeneration and diseases. Several miRNAs, including miR-1, miR-133, miR-206, miR-208, and miR-499, have been employed as molecular markers to diagnose diseases and analyze various muscle cell types. Similar to miR-133a and
miR-23a, which can inhibit muscle cell differentiation, it is highly possible there is a candidate molecular marker that can be used for the treatment of muscle diseases.

In this report, we demonstrated that circMYBPC1 could reverse the inhibitory effect of miR-23a on muscle cell differentiation, which provides evidence for a potential medical use of circMYBPC1. To date, accumulating research has shown that circRNAs are involved in the process of muscle diseases. For example, in Duchenne muscular dystrophy (DMD) myoblasts, circ-ZNF609 is involved in myogenesis control and has been reported to be translated into a protein. In this study, we revealed that circMYBPC1 not only participates in the process of muscle differentiation by inhibiting miR-23a but also directly affects muscle development by binding with MyHC. circRNA regulates muscle development through a variety of mechanisms, and its role in the treatment of muscle diseases needs to be further explored.

Conclusions
In conclusion, this study was undertaken to map the expression of circRNAs in cattle skeletal muscle. When comparing cattle muscle tissues in the adult and embryonic phases, numerous circRNAs were identified, and several of them displayed different abundances. The function of circMYBPC1, one of the highly expressed differential circRNAs in adulthood, was characterized and evaluated. Our findings suggested that circMYBPC1 regulates the development of bovine skeletal muscle by acting as a ceRNA and binding to RNA binding protein directly in vitro as well as inducing skeletal muscle regeneration in vivo. Thus, the identification and mechanism exploration of circMYBPC1 in this study provides a new molecular target for beef cattle breeding, and circMYBPC1 may be a potential therapeutic target for combating muscle diseases in the future.

MATERIALS AND METHODS
Sample preparation
Six *longissimus dorsi* muscle samples were collected from Angus cattle (90 days old, n = 3; 24 months old, n = 3), and nine tissues (liver, spleen, heart, lung, kidney, small intestine, *musculus longissimus*, leg muscle, and stomach) were collected for total RNA extraction. The animal care and research protocol for this experiment has been approved by the Animal Care Committee of the College of Animal Science and Technology of Guangxi University.

Preparation of libraries and Illumina sequencing
Total RNA was extracted from six Angus *longissimus dorsi* muscle samples with TRizol reagent (TaKaRa, Dalian, China). Gel electrophoresis, NanoDrop, Qubit 2.0, and Agilent 2100 methods were respectively used to detect integrity, to assess the yield, and to quantify the concentrations of RNA samples, so as to ensure the use of optimal samples for Illumina sequencing. Before the RNA-seq libraries were constructed, the epicenter Ribo-Zero Kit (Illumina, San Diego, CA, USA) was used to remove rRNA. Then, the samples were processed with fragments and used as templates to synthesize the first- and second-stranded complementary DNAs (cDNAs) by using random hexamer primers, deoxyribonucleotide triphosphate (dNTP), and DNA polymerase 1 (TaKaRa, Dalian, China). The
cDNA fragments were washed and concentrated with AMPure XP magnetic beads, the ends were repaired and modified with T4 DNA polymerase, and the add-A and adapters at the 3’ end of the DNA fragments were modified with Klenow DNA polymerase. The purified first-strand cDNA was PCR amplified, and the quality of the library was checked with an Agilent 2100 bioanalyzer. Finally, transcriptome sequencing was performed on the HiSeq 2500 (Illumina, San Diego, CA, USA). The raw sequence data files discussed in these experiments were deposited in the Sequence Read Archive (SRA) and can be accessed via accession numbers PRJNA639046. The data files from adult tissue accession numbers are SRA: SRR12004781, SRR12004780, and SRR12004779 and those from the embryo numbers are SRA: SRR12004778, SRR12004776, and SRR12004777.

**Treatment of raw sequencing data**

The raw data files for quality control were cleaned up with Trim Galore, and the clean data were mapped to the Bos taurus reference genome (bosTau 7) from UCSC (http://genome.ucsc.edu/) with HISAT2. Cufflinks software was used to linearize the transcript assembly and abundance assessment, and then reads from fusion transcripts that did not match the linear RNA sequences were identified. circRNAs that are <100 kb in length, with no less than two supporting sequences and no more than two mismatched sequences, were selected for further analysis.

**Identification and analysis of circRNAs**

The circRNAs were identified with CIRI2 software. The differential expression of circRNAs was analyzed by DESeq2 software.
The screening conditions were $q$ value <0.01 and $\mid \log_2$ (fold change) $\mid >1$.

**GO and pathway analysis**

GO analysis (http://geneontology.org) was performed to explore potential functions of circRNA-hosting genes. In this analysis, three different aspects of biological processes, cell components, and molecular functions are analyzed. It not only highlights the molecular functions of specific genes but also reduces complexity. KEGG analysis (https://www.kegg.jp/) was performed to analyze the biological pathways involved in host genes.

**circRNA-miRNA-mRNA competing endogenous RNA network**

Based on the binding sites of miRNAs detected in mRNA and circRNA sequences, an interaction regulation network was constructed between mRNA, miRNA, and circRNA. TargetScan (http://www.targetscan.org/vert_71/) and RNAhybrid (https://bibiserv.cbi.tau.ac.il/rnahybrid/) were used to predict the interactions of miRNA-mRNA and miRNA-circRNA, while miRcode (http://www.mircode.org/) and miRanda (http://www.mirbase.org) were employed to predict miRNA binding sites. Cytoscape software was used to display the circRNA-miRNA-mRNA interaction network.

**Plasmid construction**

Cloned circMYBPC1 mature sequence (Text S1) was ligated into the pCD2.1-cir vector (Figure S1A) (Geneseed, Guangzhou, China) at the Kpnl and NotI cutting sites to construct its expression plasmid (pCD2.1-circMYBPC1) (Figure S1B). The fragment of circMYBPC1 containing miR-23a binding sites was cloned into psi-CHECK2 vector (pCK-circMYBPC1-W). The complementary sequences of 2× miR-23a mature sequences were synthesized and inserted into psiCHECK2 to construct the sensor element. All primer sequences used are listed in Table S6. The recombinant plasmids used in the experiments were conformed by sequencing (Sangon Biotech, Shanghai, China).

**Cell culture and treatments**

The longissimus dorsi muscle (~15 cm in length) of the fetus (3 months old) was taken, and the primary muscle cells were isolated.
The cell isolation steps were performed as previously reported. Skin, fascia, and other tissues were removed from the longissimus dorsi muscle tissue of the fetus, the muscle tissue was cut into the smallest possible pieces of minced meat with ophthalmological scissors, and the minced muscle tissue was shaken with collagenase I (Life Technologies, San Francisco, CA, USA) at 37°C in a water bath for 1 h. Then, trypsinization was performed for 20–25 min, and the digestion was terminated with DMEM medium containing 10% fetal bovine serum (FBS) (Gibco, Waltham, MA, USA). The cell pellet obtained by centrifugation at 600 g was resuspended in warm DMEM (37°C) and filtered with 100 mesh and 70 mesh filters. The cell pellet obtained by centrifugation was washed 3 times with PBS. Finally, the cells were resuspended in a medium containing 20% FBS (Gibco, Waltham, MA, USA) and 1% penicillin-streptomycin (Gibco, Waltham, MA, USA). After culturing in a 37°C incubator for 2 h, the cell culture and supernatant were inoculated into a cell culture plate at 37°C and 5% CO₂ to obtain P₀ generation myoblasts for subsequent subculture. Cell differentiation is when the cell fusion reaches 80%; the differentiation medium (Gibco, Waltham, MA, USA) containing 2% horse serum is used to replace the growth medium to induce cell differentiation.

Figure 7. Effect of circMYBPC1 on cell proliferation
(A and B) Bovine primary myocytes were transfected with either pCD2.1-circMYBPC1 or pCD2.1-ciR, and the cell cycle phases were analyzed by flow cytometry. (C and D) The expression of CDK2 and PCNA were measured by quantitative real-time PCR and western blotting. (E–G) Cell proliferation analysis was also performed with Cell Counting Kit-8 (CCK-8, E) and EdU incorporation assays (F and G). The data are presented as means ± SEM for three individuals. Scale bar represents 200 μm. *p < 0.05; **p < 0.01.
Figure 8. circMYBPC1 functions as a miRNA sponge in vitro
(A) RNAhybrid predicted miR-23a binding sites at four distinct positions in circMYBPC1. (B) Cells were co-transfected with a miR-23a mimic and pCK-circMYBPC1-W. After 24 h, double fluorescence was detected with Dual-Fluorescence Kit E1910. The relative luciferase activities were firefly/Renilla ratios, with the levels induced by pCK-circMYBPC1-W equated to 1, and the figure was drawn with GraphPad software. (C) miR-23a is a sensor construct, and the blue box represents the inserted miR-23a sequence. (D) The miR-23a sensor was co-transfected with a miR-23a mimic and/or pCD2.1-circMYBPC1 into cattle primary myocytes. Renilla luciferase activity was normalized to firefly luciferase activity. (E) The association of circMYBPC1 and miR-23a with Ago2. Cellular lysates were used for RIP assays using Ago2 antibody. circMYBPC1 and miR-23a levels were detected with semiquantitative PCR. (F) Biotin-labeled miRNA was purified and subjected to RNA pull-down assays by incubation with cattle primary myoblast lysates, followed by quantitative real-time PCR analysis to measure circMYBPC1 levels. (G) The quantitative real-time PCR results show the expression of MyHC in bovine primary myoblasts, showing that circMYBPC1 can reduce the inhibitory effect of miR-23a on MyHC expression. The values are means ± SEM for three individuals. *p < 0.05; **p < 0.01.
Cell transfection
All transient bovine myoblastocytes and 293T cells were transfected with reagent R0531 (Thermo Fisher Scientific, Waltham, MA, USA) according to the manufacturer’s instructions.

Nuclear and cytoplasmic RNA fractionation
According to the manufacturer’s instructions, nuclear and cytoplasmic RNA from cattle myoblasts was isolated with the PARIS Kit (Life Technologies, San Francisco, CA, USA). Then total RNA was extracted from the nucleus and cytoplasm and transcribed into cDNA for further experiments.

CDNA synthesis and quantitative real-time PCR
Total RNA was extracted from seven tissues and cells by TRIzol reagent (Life Technologies, San Francisco, CA, USA). Two units of RNase R was added to 1 μg of total RNA and incubated for 20 min at 37°C for RNase R treatment, and the RNeasy MinElute Cleanup Kit (QIAGEN, Hilden, Germany) was employed for purification. The RNA was transformed into cDNA with the HiScript III reverse transcription kit (Vazyme, Nanjing, China). Fluorescence quantitative PCR was performed on an ABI 7500 (Thermo Fisher Scientific, Waltham, MA, USA) system (n = 3) using SYBR Green qPCR Master Mix (Vazyme, Nanjing, China). The primers used are listed in Table S5.

CCK-8 and EdU assays
The proliferation state of bovine skeletal muscle cells was investigated with CCK-8 (n = 8) (Tiandz, Beijing, China) and Cell-Light EdU Apollo 567 In Vitro Imaging Kits (RiboBio, Guangzhou, China). The detailed procedures are described in the manufacturers’ instructions. CCK-8 assay was performed at 18 h after transfection with a marker enzyme (TECAN, Männedorf, Switzerland). EdU assay (n = 3) was performed at 18 h after transfection; the results were observed and photographed under a fluorescence microscope (DM5000B, Leica, Germany).

Flow cytometry
The cell cycle phases and apoptosis were detected by flow cytometry (FACSCalibur, Becton Dickinson, USA). The cell cycle was analyzed with the Cell Cycle Testing Kit (Multisciences, Hangzhou, China). The detailed procedures are described in the manufacturers’ instructions.
Fluorescence in situ hybridization (FISH) was performed by using in situ hybridization reagents (Servicebio, Wuhan, China). Bovine myoblasts were cultured on glass slides and incubated with FISH fixative for 30 min at room temperature. They were incubated with PBS containing 0.2% Triton X-100 at room temperature for 5 min to penetrate the cell membrane and then incubated with the pre-hybridization solution at 37°C for 1 h. Then, the hybridization solution of fixed cells and fluorescently labeled circMYBPC1 probe were placed in a black wet box and incubated overnight at 4°C. The next day, the cells

Figure 10. circMYBPC1 promotes skeletal muscle regeneration
(A) Expression levels of circMYBPC1 3 days after plasmid injection to produce skeletal muscle injury. (B) Quantitative real-time PCR measurements of myogene-related genes 3 days after transfection with circMYBPC1 expression plasmid via the tibialis anterior. (C) Expression levels of circMYBPC1 7 days after plasmid injection to produce skeletal muscle injury. (D) Quantitative real-time PCR measurements of myogenesis-related genes 7 days after transfection with circMYBPC1 expression plasmid via the tibialis anterior. (E) Representative photomicrographs of H&E-stained muscle sections on the 3rd and 7th days after muscle injury. These show that the muscle damage of wild-type mice is more severe than that of mice overexpressing circMYBPC1. 0.9% normal saline was used as a control, and the magnification was 40×. (F) Muscle fiber number and muscle fiber area statistics. The data represent means ± SEM of at least three independent experiments. *p < 0.05; **p < 0.01.
Figure 11. circMYBPC1 stimulates skeletal muscle regeneration in vivo

(A) A C57BL mouse muscle injury model employed to detect the repair of muscle injury before and after overexpression of pCD2.1-circMYBPC1 by immunofluorescence, and the magnification was 40x. MyHC and MyoD antibodies (red), PAX7 and CyclinD1 antibodies (green), and 4',6-diamino-2-phenylindole (DAPI). (B and C) Fluorescence intensity of images were quantified with ImageJ software. *p < 0.05; **p < 0.01.
were washed with PBS solution five times, and 4',6-diamino-2-phenylindole (DAPI, 1:1,000) solution was added and incubated for 5 min at room temperature in the dark. The whole experiment requires the slides to be placed in a humid box to keep the cells moist. Finally, a fluorescence microscope (Nikon, Tokyo, Japan) was used for cell observation, and fluorescence photos were taken.

**Immunofluorescence staining**

The primary bovine myoblasts differentiated for 4 days were washed 3 times with PBS (pH 7.4) and then fixed for 30 min with 4% paraformaldehyde. The cells were then transfused with 0.5% Triton X-100 for 15 min and incubated with MyHC antibody (Abcam, Cambridge, UK) overnight at 4°C and then dilute goat anti-mouse IgG (H&L)-Alexa Fluor 594 (1:500; RS3608, Immunoway, USA) with 1% bovine serum albumin. Cell nuclei were stained with DAPI. Finally, the cells were washed 3 times with PBS and observed under a fluorescence microscope (DM5000B, Leica, Germany).

**Western blotting analysis**

Protein was extracted from cell samples with RIPA (Radio Immunoprecipitation Assay) lysis buffer containing 1% PMSF (Solarbio, Beijing, China). The protein concentration was determined with the BCA Kit (Beyotime, Shanghai, China). The proteins were separated with 10% SDS–polyacrylamide gel (Bio-Rad, Hercules, CA, USA) electrophoresis and transferred to polyvinylidine fluoride membranes. After the membranes were incubated with primary antibodies specific for CyclinD1, CDK2, PCNA, MyHC, MyoG, and β-actin (Abcam, Cambridge, MA, USA) and then the respective secondary antibodies, the membranes were exposed with ECL Plus (Solarbio, Beijing, China) and the images generated were captured with the ChemiDoc XRS+ system (Bio-Rad, Hercules, CA, USA).

**Dual-luciferase reporter system assay**

HEK293T cells were used to validate luciferase activity. First, wild-type or mutant-type luciferase reporter plasmids of circMYBPC1 and miRNA mimics were transfected into 293T cells to analyze their target relationships. Second, the sensor of miRNAs and circMYBPC1 expression plasmids were transfected into 293T cells to detect competition between miRNAs and circRNAs. The Dual-Luciferase Reporter (DLR) Assay System Kit (Promega, Madison, WI, USA) was then used to measure the luciferase activity according to the manufacturer’s instructions.

**RNA-binding immunoprecipitation assay**

Specific RNA molecules related to Ago2 or MyHC (Abcam, Cambridge, MA, USA) protein were identified by RNA binding protein immunoprecipitation (RIP) assay. Briefly, the experimental procedure used was as follows: (1) Cells were lysed in RLP Lysis Buffer. (2) The antibody to the RNA binding protein of Ago2 was immunoprecipitated with protein A/G magnetic beads. (3) The magnetic bead-bound complexes were immobilized with a magnet, and any unbound material was washed off. (4) The RNAs were then extracted for quantitative real-time PCR (n = 3) analysis. IgG protein was used as a control reference. The detailed procedure was performed according to the manufacturer’s instructions for the EZ-Magna RIP Kit (Millipore, Burlington, MA, USA).

**RNA pull-down assay**

The protocol of the RNA pull-down assay used in this study is consistent with that previously described. The biotinylated miR-23a mimic was synthesized (Geneseeed, Guangzhou, China) and transfected into cattle muscle cells, which were then incubated for a further 24 h. Then, streptavidin-coated magnetic beads were added and used to pull down the biotin-labeled miR-23a complex. The abundance of circMYBPC1 was subsequently measured by quantitative real-time PCR (n = 3).

**In vivo experiments**

C57BL/6 strains of SPF (specific pathogen free) experimental mice were purchased from Hunan SJA Laboratory Animal. Study protocols and animal care were approved by the Animal Care Commission of the College of Animal Science and Technology, Guangxi University. 50 μL of CTX (Biotechnology, Shanghai, China) solution (10 μM) was injected into the tibialis anterior muscle of 5-week-old mice to induce skeletal muscle injury. The expression plasmid pCD2.1-circMYBPC1 (Beijing Englin Biosystems, China) with Entrantra in vivo transfection reagent was injected into the left tibialis anterior muscle of 5 mice in each experimental group. The injection time after CTX treatment was 12 h, 48 h, and 96 h. The tibialis anterior muscle of the right leg of the mouse was used as a control group, and 50 μL of 0.9% plasmid-free physiological saline solution was injected. After CTX treatment (144 h), the RNA extraction and quantitative real-time PCR (n = 3) analysis were performed on the tibialis anterior muscles of each left hind leg and right hind leg, respectively. H&E staining was performed on these samples with a standard protocol.

**H&E staining**

Fresh tissue was fixed with 4% formaldehyde for 24 h and then dehydrated with successive 10%, 20%, and 30% sucrose solutions over a period of 24 h. The tissue was cut into cubes with a side length of 0.5 cm and then embedded with OCT (optimal cutting temperature compound, Sakura, Torrance, CA, USA) frozen section embedding agent (Sakura Tissue-Tek OCT Compound 4583) in a frozen slicer at −25°C for 10 min. Tissue sections of 5–10 μm thickness were then cut. After H & E staining, resin was used to seal the sections and observed with a fluorescence microscope (Nikon, Tokyo, Japan).

**Immunofluorescence**

Fresh tissue was fixed with 4% formaldehyde for 24 h and then dehydrated with successive 10%, 20%, and 30% sucrose solutions over a period of 24 h. The tissue was cut into cubes with a side length of 0.5 cm and embedded in a frozen slicer at −25°C for 10 min. Tissue sections of 5–10 μm thickness were then cut. The frozen slices were air-dried, blocked with PBS, incubated overnight with anti-CyclinD1, anti-MyoD, anti-MyHC, and anti-PAX 7 antibodies (Abcam, Cambridge, MA, USA), and then washed with PBS and re-incubated with a secondary antibody at 37°C for 1 h. The samples were washed and incubated with DAPI solution at room temperature for 15 min.
Finally, PBS was used to wash the sample three times, and a fluorescence microscope (DM5000B, Leica, Germany) was used for observation.

Statistical analysis
All data are presented as mean ± SEM. The differences between groups were determined by the Student’s t test. p <0.05 was considered to be statistically significant.

Data availability
The raw sequence data files discussed in this experiment have been deposited in Sequence Read Archive (SRA) under SRA: PRJNA639046 (https://dataview.ncbi.nlm.nih.gov/object/PRJNA639046?reviewer=ea7nkltsp9tcvurjbciajiorsf).

SUPPLEMENTAL INFORMATION
Supplemental information can be found online at https://doi.org/10.1016/j.omtn.2021.03.004.

ACKNOWLEDGMENTS
The tissue materials were taken with informed consent, and this was approved by the Institutional Animal Care and Use Committee at the College of Animal Science and Technology, Guangxi University. This work was supported by the Guangxi Natural Science Foundation (grant no. 2018GXNSFAA050086); China Postdoctoral Science Foundation (grant no. 2019M663842); Science and Technology Major Project of Guangxi (grant no. AA17204051); National Natural Science Foundation of China (grant no. 31802043); and Innovation Project of Guangxi Graduate Education (grant nos. YCSW2019027 and YCSW2019028). The authors would like to thank Dr. Dev Sooranna, Imperial College London, for editing the manuscript.

AUTHOR CONTRIBUTIONS
D.S., H.L., and Q.L. designed the study. H.L., M.C., and M.S. performed the experiments and drafted the manuscript. K.H., M.C., Y.D., and Q.L. helped to perform the experiments and analyzed the data. X.W. and R.J. helped to collect tissue samples. All the authors read and approved the final manuscript.

DECLARATION OF INTERESTS
The authors declare no competing interests.

REFERENCES
1. Buckingham, M. (2006). Myogenic progenitor cells and skeletal myogenesis in vertebrates. Curr. Opin. Genet. Dev. 16, 525–532.
2. Buckingham, M., Rajaard, L., Chang, T., Daubas, P., Hadchouel, J., Melhac, S., Montarras, D., Rocancourt, D., and Relax, F. (2003). The formation of skeletal muscle: from somite to limb. J. Anat. 202, 59–68.
3. Bailey, P., Holowacz, T., and Lasar, A.B. (2001). The origin of skeletal muscle stem cells in the embryo and the adult. Curr. Opin. Cell Biol. 13, 679–689.
4. Dirks, A., and Leeuwenburgh, C. (2002). Apoptosis in skeletal muscle with aging. Am. J. Physiol. Regul. Integr. Comp. Physiol. 282, R519–R527.
5. Braun, T., and Gautel, M. (2011). Transcriptional mechanisms regulating skeletal muscle differentiation, growth and homeostasis. Nat. Rev. Mol. Cell Biol. 12, 349–361.
6. Hernández-Hernández, J.M., García-González, E.G., Brun, C.E., and Rudnicki, M.A. (2017). The myogenic regulatory factors, determinants of muscle development, cell identity and regeneration. Semin. Cell Dev. Biol. 72, 10–18.
7. Naya, F.I., and Olson, E. (1999). MEF2: a transcriptional target for signaling pathways controlling skeletal muscle growth and differentiation. Curr. Opin. Cell Biol. 11, 683–688.
8. Sabourin, L.A., and Rudnicki, M.A. (2000). The molecular regulation of myogenesis. Clin. Genet. 57, 16–25.
9. Mok, G.F., Lozano-Velasco, E., and Münsterberg, A. (2017). microRNAs in skeletal muscle development. Semin. Cell Dev. Biol. 72, 67–76.
10. Li, Y., Chen, X., Sun, H., and Wang, H. (2018). Long non-coding RNAs in the regulation of skeletal myogenesis and muscle diseases. Cancer Lett. 417, 58–64.
11. Legnini, I., Di Timoteo, G., Rossi, F., Morlando, M., Briganti, F., Stendardi, O., Fatica, A., Santini, T., Andronache, A., Wade, M., et al. (2017). Circ-ZNF609 Is a Circular RNA that Can Be Translated and Functions in Myogenesis. Mol. Cell 66, 22–37.e9.
12. Nigro, J.M., Cho, K.R., Fearon, E.R., Kern, S.E., Ruppert, J.M., Oliner, J.D., Kinzler, K.W., and Vogelstein, B. (1991). Scrambled exons. Cell 64, 607–613.
13. Jeck, W.R., and Sharpless, N.E. (2014). Detecting and characterizing circular RNAs. Nat. Biotechnol. 32, 453–461.
14. Menczak, S., Jens, M., Elefieri, A., Torii, F., Krueger, J., Rybak, A., Maier, L., Mackowiak, S.D., Gregersen, L.H., Munschauer, M., et al. (2013). Circular RNAs are a large class of animal RNAs with regulatory potency. Nature 495, 333–338.
15. Jeck, W.R., Sorrentino, J.A., Wang, K., Slevin, M.K., Burd, C.E., Liu, J., Marzluff, W.F., and Sharpless, N.E. (2013). Circular RNAs are abundant, conserved, and associated with ALU repeats. RNA 19, 141–157.
16. Zheng, Q., Bao, C., Guo, W., Li, S., Chen, J., Chen, B., Luo, Y., Lyu, D., Li, Y., Shi, G., et al. (2016). Circular RNA profiling reveals an abundant circHIPK3 that regulates cell growth by sponging multiple miRNAs. Nat. Commun. 7, 11215.
17. Guo, J.U., Agarwal, V., Guo, H., and Bartel, D.P. (2014). Expanded identification and characterization of mammalian circular RNAs. Genome Biol. 15, 409.
18. Hansen, T.B., Jensen, T.J., Clausen, B.H., Bramsen, J.B., Finsen, B., Damgaard, C.K., and Kjaer, J. (2013). Natural RNA circles function as efficient microRNA sponges. Nature 495, 384–388.
19. Li, H., Wei, X., Yang, J., Dong, D., Hao, D., Huang, Y., Lan, X., Plath, M., Lei, C., Ma, Y., et al. (2018). circFGFR4 promotes differentiation of myoblasts via binding miR-107 to relieve its inhibition of Wnt3a. Mol. Ther. Nucleic Acids 11, 272–283.
20. Li, H., Yang, J., Wei, X., Song, C., Dong, D., Huang, Y., Lan, X., Plath, M., Lei, C., Ma, Y., et al. (2018). CircFUT10 reduces proliferation and facilitates differentiation of myoblasts by sponging miR-133a. J. Cell. Physiol. 233, 4643–4651.
21. Wei, X., Li, H., Yang, J., Hao, D., Dong, D., Huang, Y., Lan, X., Plath, M., Lei, C., Lin, F., et al. (2017). Circular RNA profiling reveals an abundant circLMO7 that regulates myoblasts differentiation and survival by sponging miR-378a-3p. Cell Death Dis. 8, e3153.
22. Li, Z., Huang, C., Bao, C., Chen, L., Lin, M., Wang, X., Zhong, G., Yu, B., Hu, W., Dai, L., et al. (2015). Exon-intron circular RNAs regulate transcription in the nucleus. Nat. Struct. Mol. Biol. 22, 256–264.
23. Chen, X., OuYang, H., Wang, Z., Chen, B., and Nie, Q. (2018). A Novel Circular RNA Generated by FGFR2 Gene Promotes Myoblast Proliferation and Differentiation by Sponging miR-133a-5p and miR-29b-1-5p. Cells 7, 199.
24. Wang, X., Cao, X., Dong, D., Shen, X., Cheng, J., Jiang, R., Yang, Z., Peng, S., Huang, Y., Lan, X., et al. (2019). Circular RNA TTN Acts As a miR-432 Sponger to Facilitate Proliferation and Differentiation of Myoblasts via the IGF2/PI3K/AKT Signaling Pathway. Mol. Ther. Nucleic Acids 32, 453–464.
25. Xiong, Y., Zhang, J., and Song, C. (2019). CircRNA ZNF609 functions as a competent endogenous RNA to regulate FOXF4 expression by sponging miR-138-5p in renal carcinoma. J. Cell. Physiol. 234, 10646–10654.
26. Wang, L., Chen, X., Zheng, Y., Li, F., Lu, Z., Chen, C., Liu, J., Wang, Y., Peng, Y., Shen, Z., et al. (2012). MiR-23a inhibits myogenic differentiation through down regulation of fast myosin heavy chain isoforms. Exp. Cell Res. 318, 2324–2334.
27. Shen, L., Chen, L., Zhang, S., Zhang, Y., Wang, J., and Zhu, L. (2016). MicroRNA-23a reduces slow myosin heavy chain isoforms composition through myocyte enhancer factor 2C (MEF2C) and potentially influences meat quality. Meat Sci. 116, 201–206.

28. Das, A., Das, A., Das, D., Abdelmohsen, K., and Panda, A.C. (2020). Circular RNAs in myogenesis. Biochim. Biophys. Acta. Gene Regul. Mech. 1863, 194372.

29. Liu, C.X., Li, X., Nan, F., Jiang, S., Gan, X., Guo, S.K., Xue, W., Cui, Y., Dong, K., Ding, H., et al. (2019). Structure and degradation of circular RNAs regulate PKR activation in innate immunity. Cell 177, 865–880.e21.

30. Kristensen, L.S., Hansen, T.B., Venø, M.T., and Kjems, J. (2018). Circular RNAs in cancer: opportunities and challenges in the field. Oncogene 37, 555–565.

31. Bryson-Richardson, R.J., and Currie, P.D. (2008). The genetics of vertebrate myogenesis. Nat. Rev. Genet. 9, 632–646.

32. Chen, J.F., Mandel, E.M., Thomson, J.M., Wu, Q., Callis, T.E., Hammond, S.M., Conlon, F.L., and Wang, D.Z. (2006). The role of microRNA-1 and microRNA-133 in skeletal muscle proliferation and differentiation. Nat. Genet. 38, 228–233.

33. Ding, J., Chen, J., Wang, Y., Kataoka, M., Ma, L., Zhou, P., Hu, X., Lin, Z., Nie, M., Deng, Z.L., et al. (2015). Trbp regulates heart function through microRNA-mediated Sox6 repression. Nat. Genet. 47, 776–783.

34. Zeng, H.C., Bae, Y., Dawson, B.C., Chen, Y., Bertin, T., Munivez, E., Campeau, P.M., Tao, L., Chen, R., and Lee, B.H. (2017). MicroRNA miR-23a cluster promotes osteocyte differentiation by regulating TGF-β signalling in osteoblasts. Nat. Commun. 8, 15000.

35. Wüst, S., Dröse, S., Heidler, J., Wittig, I., Klockner, I., Franko, A., Bonke, E., Günther, S., Gärtner, U., Boettger, T., and Braun, T. (2018). Metabolic Maturation during Muscle Stem Cell Differentiation Is Achieved by miR-1/133a-Mediated Inhibition of the Dlk1-Dio3 Mega Gene Cluster. Cell Metab. 27, 1026–1039.e6.

36. Li, H., Yang, J., Jiang, R., Wei, X., Song, C., Huang, Y., Lan, X., Lei, C., Ma, Y., Hu, L., and Chen, H. (2018). Long Non-coding RNA Profiling Reveals an Abundant MDNCR that Promotes Differentiation of Myoblasts by Sponging miR-133a. Mol. Ther. Nucleic Acids 12, 610–625.

37. Li, X., Liu, C.X., Xue, W., Zhang, Y., Jiang, J., Yin, Q.F., Wei, J., Yao, R.W., Yang, L., and Chen, L.L. (2017). Coordinated circRNA Biogenesis and Function with NF90/ NF110 in Viral Infection. Mol. Cell 67, 214–227.e7.

38. Lal, A., Thomas, M.P., Altschuler, G., Navarro, F., O’Day, E., Li, X.L., Concepcion, C., Han, Y.C., Thiery, J., Rajani, D.K., et al. (2011). Capture of microRNA-bound mRNAs identifies the tumor suppressor miR-34a as a regulator of growth factor signaling. PLoS Genet. 7, e1002363.
Supplemental information

Circular RNA circMYBPC1 promotes skeletal muscle differentiation by targeting MyHC

Mengjie Chen, Xuefeng Wei, Mingming Song, Rui Jiang, Kongwei Huang, Yanfei Deng, Qingyou Liu, Deshun Shi, and Hui Li
Text S1. Sequence of circMYBPC1.

circMYBPC1
ATACATCTTTGAAACATAAAGGATGTGAAAGAATCATGTTTTAATCAATAACTGTGTACT
AACAGATGATTCGGAGTATTATGTGACAGCTGGTGGATGAGAAATGTTCACACTGAC
TCTTTGTGAGAGAGCCTCCACTTTATGACCTGGACAAACAGCTGGGAGATACAAAGC
TTAATTATGGAGAGATGGAATTATGAATGTGAAGTGTCTGAAGATGAGCCAATG
TTAAATGGTTAAGAAATGGTAGGGAAATCATCCCCCGGGGAAAATCAAGATCCAC
ATTAGATTGAAAAGCAATTCATTTTGATCATAGATGGAGGACAAAAGGCTG
ATTCTGCAGAATATTCTGTCAATGACAAAAGGAGGACAGTCATCTGCTAAAATTTAGT
GTGGACT
Text S2. Online prediction of the bovine circMYBPC1 sequence revealed the presence of four miR-23a binding sites.

Version: RNAhybrid 2.2

Command line:/vol/bioapps/bin/RNAhybrid.bin -b 4 -D -n 23 -m 398 -q /var/bibiserv2/anonymous/rnahybrid/24/11/15/bibiserv2_2019-05-24_111550_aabZo/rnahybrid_input_mirna_sequences.file -t /var/bibiserv2/anonymous/rnahybrid/24/11/15/bibiserv2_2019-05-24_111550_aabZo/rnahybrid_input_target_rna_sequences_.file

searching

dataset: 1

MYBPC1e of bta-miR-23a: -46.299995

Individual hits

------------------------------------------------------------
dataset: 1
target: circMYBPC1
length: 398
miRNA : bta-miR-23a
length: 22
mfe: -25.7 kcal/mol
p-value: undefined
position  246

| target 5' A | AUC | C | 3' |
|-------------|-----|---|----|
| GGAA        | AUCCCUGGU |
| CCUU        | UAGGGACCG |

| miRNA 3' A | UUACACUA 5' |
|------------|-------------|

------------------------------------------------------------
dataset: 1
target: circMYBPC1
length: 398
miRNA : bta-miR-23a
length: 22
mfe: -23.2 kcal/mol
p-value: undefined
position 93

5' A A UGU A A UCUU G 3'
    UG GAAA UCC CUG GC UGUGA
    AC CUUU AGG GAC CG ACACU

3' UU A 5'

dataset: 1
target: circMYBPC1
length: 398
miRNA: bta-miR-23a
length: 22
mfe: -20.5 kcal/mol
p-value: undefined
position 177

5' G GAG AAUUAG A 3'
    GGAGA UGG AAUGUGA
    CCUUU ACC UUACACU

3' A AGGG G A 5'

dataset: 1
target: circMYBPC1
length: 398
miRNA: bta-miR-23a
length: 22
mfe: -20.3 kcal/mol
p-value: undefined
position 367
Table S3. Kyoto Encyclopedia of Genes and Genomes pathway enrichment analysis.

| pathway_term                                      | rich_factor | qvalue     | gene_number |
|---------------------------------------------------|-------------|------------|-------------|
| Fatty acid metabolism                             | 0.12766     | 0.2072     | 6           |
| Oxytocin signaling pathway                        | 0.065359    | 0.300575   | 10          |
| cGMP-PKG signaling pathway                        | 0.05988     | 0.300575   | 10          |
| Gastric acid secretion                            | 0.081081    | 0.300575   | 6           |
| Lysine degradation                                | 0.092593    | 0.300575   | 5           |
| Retrograde endocannabinoid signaling              | 0.067308    | 0.300575   | 7           |
| Inflammatory mediator regulation of TRP channels  | 0.066667    | 0.300575   | 7           |
| Calcium signaling pathway                         | 0.053191    | 0.300575   | 10          |
| Biosynthesis of unsaturated fatty acids           | 0.136364    | 0.300575   | 3           |
| GnRH signaling pathway                            | 0.068966    | 0.300575   | 6           |
| Fatty acid elongation                             | 0.130435    | 0.300575   | 3           |
| Glutamatergic synapse                             | 0.06087     | 0.300575   | 7           |
| Pancreatic secretion                              | 0.063158    | 0.358122   | 6           |
| PPAR signaling pathway                            | 0.070423    | 0.358122   | 5           |
| Fatty acid biosynthesis                           | 0.153846    | 0.521561   | 2           |
| Proteoglycans in cancer                           | 0.044776    | 0.534605   | 9           |
| Long-term depression                              | 0.066667    | 0.585082   | 4           |
| Gap junction                                      | 0.05618     | 0.601209   | 5           |
| Long-term potentiation                            | 0.060606    | 0.660681   | 4           |
| Fatty acid degradation                            | 0.071429    | 0.660681   | 3           |
Table S5. Primers for quantitative real time PCR.

| Name          | Forward primer 5’→3’                      | Reverse primer 5’→3’                        |
|---------------|------------------------------------------|---------------------------------------------|
| CircMYBPC1    | AGTGTGGACTTACATCACTTTGTGAACA             | TGGTCACCATAACTGGGAGGC                       |
| PCNA-bos      | TCCAGAACAAGAGATATAGC                     | TACAACAGCATCTCCAAAT                        |
| β-actin-bos   | CATCCTGACCCCTCAAGTA                      | CTCGTTTGAAGGTGTG                           |
| MyoG-bos      | CAAATCCACCTCCCTGAAA                      | GCATAGGAAGAGATGAACA                        |
| MyhC-bos      | TGCTCATCTCAACAAAGTTCC                    | CACTCTTCACCTCTCATGGGACC                    |
| MyoD-bos      | ACGGCATGATGGACTACAGC                     | AGGCAGTCGGAGCTCGACA                        |
| bta-miR-23a   | AUCACAUUGCCAGGGAUUUCCA                   | GCAGGGGTCGGAGGTATTC                       |
| U6            | GCTTCGGCAGCACATATACTAAAT                 | CGTTTACGAAATTGTGCAGTGCAT                  |
| PCNA-mus      | ACTCCGCCACATGTTTTGAGG                   | TCGCAGCGGTATGTGTCGAAG                      |
| β-actin-mus   | CAAGAGAGGTATCCTGACCCT                   | TGATCTGGGTGACTCTTTTCA                      |
| MyoG-mus      | CCGTGGGCATGTAGGTGTG                      | ACTTTAGGCAGCCGCTGTTG                      |
| Myhc-mus      | CCCGCTGGCCATGAACTACCT                    | CGGGCCGGAAGAGGTGTCAG                      |
| MyoD-mus      | CCGAGTGCCAGAAAGTGAAG                     | GGCCTGTAAGTCTATGTCCC                      |
| CyclinD-mus   | CCCGCTGGCCATGAACTACCT                    | CGGGCCGGAAGAGGTGTCAG                      |
| CDK2-mus      | AGGTCTCCCGCTCGAGAGTGC                   | CGCCACAACCTTCCCGTCAAA                     |
| Pax3-mus      | TCGTCTCGGCTTCACTCAG                      | AGCCGCTGCGGTGGAATTCTCT                    |
| Pax7-mus      | GGACGACGAGGAAGGAGGAC                    | CGGGTTTGTAGTTCACACTG                      |
| P53-mus       | TGCCATGGAGGAGTCACTAGTC                   | ACACTCGGAGGCTCTCAGT                       |
| Bcl2-mus      | GCGTTGGCCCTTCGGAGTTTA                    | CACCCGGAGGCTTCGACACT                      |
| Name                  | Primer sequence 5’→3’                                                                 |
|-----------------------|----------------------------------------------------------------------------------------|
| pCD2.1-circMYBPC1-F   | GGGGTACCACCACATACATTAGTTGAAAGGCAAAA                                                    |
| pCD2.1-circMYBPC1-R   | CGGGATCTCTTTGATTGGGACCAAGGGATG                                                          |
| pCK-circMYBPC1-W-F    | CCGCTCGAGACACATTAGTTGAAAGGCAAAA                                                         |
| pCK-circMYBPC1-W-R    | ATAAGAATGCGGCCGCTTGGATTGGACCAGGGATG                                                    |
| pCK-miR-23a 2×-F      | GCTCGAGTGGAAATCCCTGGCAATGTGAT                                                           |
|                       | TGGAATCCCTGGCAATGTGAT                                                                   |
| pCK-miR-23a 2×-R      | GCGGCGCATCACATGGCAGGGATTCCA                                                            |
|                       | ATCACATGGCCAGGGATTTCCA                                                                  |

Notes: The nucleotide with underline is the restriction enzyme cutting site.
Figure S1. (A) A map of circular RNA expression vector. (B) Schematic view illustrating the design of primers for circRNAs used in qPCR. (C) Schematic view illustrating the design of primers for circRNAs used in qPCR. (D) circMYBPC1 consists of three exons.
Figure S2. (A) Calculate the amount of gene expression in the Western blot experiment in Figure 6B. (B) qPCR results showing that MyHC were highly expressed in muscle tissues including the musculus longissimus, leg muscle.